ArticleOrphanet journal of rare diseases2025
Six Chinese patients with propionic acidemia: from asymptomatic to death in the neonatal period.
Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPropionic acidemia (PA) is a severe organic acidemia that can result in multi-organ damage and is potentially fatal. The rarity of this disease and the limited number of reported cases contribute to a lack of comprehensive knowledge, particularly concerning the genotype-phenotype correlation. This study aims to report on PA cases in Beijing and Ningxia, China, identify the pathogenic genetic factors involved, and explore the relationship between genotype and phenotype.
methodsWe calculated the positive screening rates of PA in Beijing and Ningxia and summarized data from six Chinese patients with PA identified at the Beijing Newborn Screening Center and Ningxia Newborn Screening Center. Clinical examinations included blood tandem mass spectrometry, urine gas chromatography-mass spectrometry, and the next-generation sequencing (NGS) technology. Candidate mutations were validated using polymerase chain reaction and Sanger sequencing technology. Bioinformatics software was used to analyze the pathogenicity of the variants, and Swiss PDB Viewer software was employed to predict the effect of mutations on PCCA and PCCB proteins.
resultsThe updated incidence of PA was 1 in 114,820 in Beijing and 1 in 189,671 in Ningxia. We reported five patients diagnosed with PA through newborn screening (NBS) and one additional patient diagnosed clinically. Among the five patients diagnosed by NBS, the two late-onset patients exhibited normal neurodevelopment, while all three early-onset patients succumbed between 4 days and 18 months of age. The patient diagnosed clinically passed away at 20 days of age. NGS showed one patient carries compound mutations in the PCCA gene and three patients carry compound heterozygous or homozygous mutations in the PCCB gene. A total of two mutations in PCCA (c.985T > A and c.1195 C > T) and five mutations in PCCB (c.1076 C > T, c.1087T > C, c.224 A > C, c.1339 C> T, and c.1033G > C)were identified, including one novel PCCA mutation (c.985T > A) and four novel PCCB mutations (c.1076 C > T, c.224 A > C, c.1339 C> T, and c.1033G > C). Bioinformatics analysis indicated these mutations are pathogenic, and Swiss PDB Viewer predictions suggest that these variations affect protein conformation.
conclusionsThe updated incidence rates of PA in Beijing and Ningxia provide new epidemiological insights. We reported six patients with PA, and identified one novel mutation (c.985T > A) in PCCA and four novel mutations (c.1076 C > T, c.224 A > C, c.1339 C> T, and c.1033G > C) in PCCB, which expands the spectrum of clinical features and genetic mutations associated with PA. The c.985T > A mutation in PCCA and the c.1076 C > T mutation in PCCB may be associated with late-onset PA, while the c.224 A > C, c.1339 C > T, and c.1033G > C mutations in PCCB are related to early-onset PA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.